2 Gurus Talk Compliance: Episode 55 – The From Worse to Worser Edition
First 100 Days of the New HSR Rules with Antitrust Partner Kara Kuritz
The LathamTECH Podcast — Getting Deals Done: Tackling Antitrust Challenges in Tech M&A
Daily Compliance News: June 2, 2025, The Unintended Consequence Edition
Podcast - Navigating the New Landscape of Private Equity in Healthcare
10 For 10: Top Compliance Stories For the Week Ending May 17, 2025
From Cell Phones to Tractors: The Right to Repair Movement Drives On — Regulatory Oversight Podcast
Daily Compliance News: May 12, 2025, The Corruption in the Broad Daylight Edition
Daily Compliance News: May 1, 2025, The 100 Days of Corruption Edition
Daily Compliance News: April 23, 2025, The R-E-S-P-E-C-T Edition
Business Better Podcast Episode: Bridging Campuses: Legal Insights on Education Industry Consolidation – Mergers, Acquisitions, and Antitrust
Antitrust Insights for Private Equity Navigating the New Administration's Policies — PE Pathways Podcast
12 Days of Regulatory Insights: Day 11 – State AGs on the Antitrust Frontline — Regulatory Oversight Podcast
12 Days of Regulatory Insights: Day 8 - Inside the Texas AG's Office — Regulatory Oversight Podcast
12 Days of Regulatory Insights: Day 3 - State AG Oversight in the Health Care Industry — Regulatory Oversight Podcast
Episode 341 -- DOJ Charges Visa with Monopolization and Exclusionary Conduct in the Debit Card Market
Fierce Competition Podcast | Antitrust Challenges in Organized Sports: How They Play Out in the EU, UK and US
Podcast: Key Changes in Finalized Antitrust Merger Guidelines – Diagnosing Health Care
The Changing Landscape of State AG Antitrust Enforcement — Regulatory Oversight Podcast
Fierce Competition Podcast | Takeaways From the Illumina-Grail Merger Challenge Saga
Pending proposals to amend China's Anti-Unfair Competition Law (AUCL) may further blur the line between antitrust and anti-corruption offenses under China's enigmatic "counterparty bribery" rules. The AUCL, first enacted in...more
On May 28, the Federal Trade Commission (“FTC”) announced it had reached a $1.2 billion settlement with Teva Pharmaceuticals, which acquired Cephalon in 2012, over reverse payment for its narcolepsy drug, Provigil. The...more